GCPII imaging and cancer

Current Medicinal Chemistry

Volumn 19, Issue 9, 2012, Pages 1346-1359

  Foss, C A ^a   Mease, R C ^a   Cho, S Y ^a   Kim, H J ^a   Pomper, M G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

molecular imaging; PET; prostate cancer; Prostate specific membrane antigen; PSMA; SPECT

Indexed keywords

(16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE) F 18; (3' DEOXY 3' FLUOROTHYMIDINE) F 18; 16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; 2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; [1 (2' DEOXY 2' FLUORO BETA DEXTRO ARABINOFURANOSYL)THYMINE F 18; [N [N (1,3 DICARBOXYPROPYL)CARBAMOYL] 4 FLUOROBENZYL CYSTEINE F 18; ANTI 1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID F 18; CAPROMAB PENDETIDE IN 111; CISPLATIN; DOXORUBICIN; FLUOROCHOLINE F 18; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; MEDRONIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3/A12; MONOCLONAL ANTIBODY 3/F11; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER DIAGNOSIS; DRUG TARGETING; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIGENS, SURFACE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; HUMANS; MALE; MOLECULAR IMAGING; NEOPLASMS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84863230983     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799462612     Document Type: Review

References (219)

1. Halsted, C. H., The intestinal absorption of folates. The American journal of clinical nutrition 1979, 32 (4), 846-55. (Pubitemid 9164733)
2. Sirotnak, F. M.; Tolner, B., Carrier-mediated membrane transport of folates in mammalian cells. Annual review of nutrition 1999, 19, 91-122. (Pubitemid 29380598)
3. Fowler, B., The folate cycle and disease in humans. Kidney International. Supplement 2001, 78, S221-9. (Pubitemid 32144102)
4. Moran, R. G., Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Seminars in Oncology 1999, 26 (2 Suppl 6), 24-32.
5. Ghosh, A.; Heston, W. D., Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004, 91 (3), 528-39.
6. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C., Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3 (1), 81-5. (Pubitemid 27079448)
7. Mhawech-Fauceglia, P.; Zhang, S.; Terracciano, L.; Sauter, G.; Chadhuri, A.; Herrmann, F. R.; Penetrante, R., Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007, 50 (4), 472-83. (Pubitemid 46328190)
8. Rovenska, M.; Hlouchova, K.; Sacha, P.; Mlcochova, P.; Horak, V.; Zamecnik, J.; Barinka, C.; Konvalinka, J., Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. The Prostate 2008, 68 (2), 171-82. (Pubitemid 351186229)
9. Antunes, A. A.; Leite, K. R.; Sousa-Canavez, J. M.; Camara-Lopes, L. H.; Srougi, M., The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. The Journal of Urology 2009, 181 (2), 594-600.
10. Samplaski, M. K.; Heston, W.; Elson, P.; Magi-Galluzzi, C.; Hansel, D. E., Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern Pathology 2011, 24(11), 1521-1529.
11. Wang, W.; Tavora, F.; Sharma, R.; Eisenberger, M.; Netto, G. J., PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urologic Oncology 2009, 27 (5), 525-8.
12. Chang, S. S.; O'Keefe, D. S.; Bacich, D. J.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B., Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999, 5 (10), 2674-81. (Pubitemid 29493938)
13. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B., Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59 (13), 3192-8. (Pubitemid 29316022)
14. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B., Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 2001, 57 (4), 801-5.
15. Haffner, M. C.; Kronberger, I. E.; Ross, J. S.; Sheehan, C. E.; Zitt, M.; Muhlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X. J.; Geley, S.; Margreiter, R.; Bander, N. H., Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology 2009, 40 (12), 1754-61.
16. Ilyssa O Gordon, M. S. T., Amy E Noffsinger, John Hart, Victor E Reuter and Hikmat A Al-Ahmadie, Prostate-specific membrane antigen expression in regeneration and repair. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008, 21 (12), 1421-1427.
17. DeMarzo, A. M.; Nelson, W. G.; Isaacs, W. B.; Epstein, J. I., Pathological and molecular aspects of prostate cancer. Lancet 2003, 361 (9361), 955-64. (Pubitemid 36332115)
18. Su, S. L.; Huang, I. P.; Fair, W. R.; Powell, C. T.; Heston, W. D., Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Research 1995, 55 (7), 1441-3.
19. Heston, W. D., Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997, 49 (3A Suppl), 104-12.
20. Grauer, L. S.; Lawler, K. D.; Marignac, J. L.; Kumar, A.; Goel, A. S.; Wolfert, R. L., Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer research 1998, 58 (21), 4787-9. (Pubitemid 28503668)
21. Yao, V.; Parwani, A.; Maier, C.; Heston, W. D.; Bacich, D. J., Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res 2008, 68 (21), 9070-7.
22. Wright, G. L., Jr.; Haley, C.; Beckett, M. L.; Schellhammer, P. F., Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology 1995, 1 (1), 18-28.
23. Denmeade, S. R.; Sokoll, L. J.; Dalrymple, S.; Rosen, D. M.; Gady, A. M.; Bruzek, D.; Ricklis, R. M.; Isaacs, J. T., Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate 2003, 54 (4), 249-57. (Pubitemid 36228161)
24. Birtle, A. J.; Freeman, A.; Masters, J. R.; Payne, H. A.; Harland, S. J., Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL. BJU International 2005, 96 (3), 303-7. (Pubitemid 41097670)
25. Evans, M. J.; Smith-Jones, P. M.; Wongvipat, J.; Navarro, V.; Kim, S.; Bander, N. H.; Larson, S. M.; Sawyers, C. L., Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011, 108 (23), 9578-82.
26. Mannweiler, S.; Amersdorfer, P.; Trajanoski, S.; Terrett, J. A.; King, D.; Mehes, G., Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathology Oncology Research : POR 2009, 15 (2), 167-72.
27. Wright, G. L., Jr.; Grob, B. M.; Haley, C.; Grossman, K.; Newhall, K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P. F.; Moriarty, R., Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48 (2), 326-34. (Pubitemid 26279634)
28. Lai, C. L.; van den Ham, R.; van Leenders, G.; van der Lugt, J.; Mol, J. A.; Teske, E., Histopathological and immunohistochemical characterization of canine prostate cancer. The Prostate 2008, 68 (5), 477-88. (Pubitemid 351500208)
29. Lai, C. L.; van den Ham, R.; van Leenders, G.; van der Lugt, J.; Teske, E., Comparative characterization of the canine normal prostate in intact and castrated animals. The Prostate 2008, 68 (5), 498-507. (Pubitemid 351500210)
30. Yao, V.; Bacich, D. J., Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. The Prostate 2006, 66 (8), 867-75.
31. Yao, V.; Berkman, C. E.; Choi, J. K.; O'Keefe, D. S.; Bacich, D. J., Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. The Prostate 2010, 70 (3), 305-16.
32. Barwe, S. P.; Maul, R. S.; Christiansen, J. J.; Anilkumar, G.; Cooper, C. R.; Kohn, D. B.; Rajasekaran, A. K., Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol 2007, 30 (4), 899-904.
33. Ananias, H. J.; van den Heuvel, M. C.; Helfrich, W.; de Jong, I. J., Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. The Prostate 2009, 69 (10), 1101-8.
34. Mahadevan, D.; Saldanha, J. W., The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: implications for drug design. Protein science : a publication of the Protein Society 1999, 8 (11), 2546-9.
35. Lambert, L. A.; Mitchell, S. L., Molecular Evolution of the Transferrin Receptor/Glutamate Carboxypeptidase II Family. J Mol Evol 2007, 64 (1), 113-28. (Pubitemid 46020864)
36. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G.; Maddon, P. J.; Heston, W. D.; Olson, W. C., The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America 2003, 100 (22), 12590-5. (Pubitemid 37339943)
37. Dautry-Varsat, A., Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor. Biochimie 1986, 68 (3), 375-81. (Pubitemid 16075046)
38. Commandeur, L. C.; Parsons, J. R., Degradation of halogenated aromatic compounds. Biodegradation 1990, 1 (2-3), 207-20.
39. Carrasquillo, J., Imaging and dosimetry determinations using radiolabeled antibodies. Cancer Treatment and Research 1993, 68, 65-97.
40. Grant, B. D.; Donaldson, J. G., Pathways and mechanisms of endocytic recycling. Nature reviews. Molecular cell biology 2009, 10 (9), 597-608.
41. Barinka, C.; Sacha, P.; Sklenar, J.; Man, P.; Bezouska, K.; Slusher, B. S.; Konvalinka, J., Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein science : a publication of the Protein Society 2004, 13 (6), 1627-35.
42. Ghosh, A.; Heston, W. D., Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. The Prostate 2003, 57 (2), 140-51. (Pubitemid 37204495)
43. Holmes, E. H.; Greene, T. G.; Tino, W. T.; Boynton, A. L.; Aldape, H. C.; Misrock, S. L.; Murphy, G. P., Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. The Prostate. Supplement 1996, 7, 25-9. (Pubitemid 26412173)
44. Denmeade, S. R.; Litvinov, I.; Sokoll, L. J.; Lilja, H.; Isaacs, J. T., Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate 2003, 56 (1), 45-53. (Pubitemid 36613155)
45. Laidler, P.; Dulinska, J.; Lekka, M.; Lekki, J., Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Archives of Biochemistry and Biophysics 2005, 435 (1), 1-14. (Pubitemid 40170010)
46. Conway, R. E.; Petrovic, N.; Li, Z.; Heston, W.; Wu, D.; Shapiro, L. H., Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Molecular and Cellular Biology 2006, 26 (14), 5310-24. (Pubitemid 44036201)
47. Duda, D. G.; Fukumura, D.; Jain, R. K., Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends in Molecular Medicine 2004, 10 (4), 143-5. (Pubitemid 38410970)
48. Bivalacqua, T. J.; Musicki, B.; Usta, M. F.; Champion, H. C.; Kadowitz, P. J.; Burnett, A. L.; Hellstrom, W. J., Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Current Pharmaceutical Design 2005, 11 (31), 4059-67. (Pubitemid 41672477)
49. Antony, A. C., Folate receptors. Annual Review of Nutrition 1996, 16, 501-21. (Pubitemid 26286863)
50. Matherly, L. H.; Goldman, D. I., Membrane transport of folates. Vitamins and Hormones 2003, 66, 403-56.
51. Elnakat, H.; Ratnam, M., Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Advanced Drug Delivery Reviews 2004, 56 (8), 1067-84. (Pubitemid 38496508)
52. Bailey, L. B., Folate status assessment. The Journal of Nutrition 1990, 120 Suppl 11, 1508-11.
53. Rader, J. I., Folic acid fortification, folate status and plasma homocysteine. The Journal of Nutrition 2002, 132 (8 Suppl), 2466S-2470S. (Pubitemid 34848128)
54. Marin, Y. E.; Chen, S., Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. Journal of Molecular Medicine 2004, 82 (11), 735-49. (Pubitemid 40022267)
55. Haas, H. S.; Linecker, A.; Pfragner, R.; Sadjak, A., Peripheral glutamate signaling in head and neck areas. Head & Neck 2010, 32 (11), 1554-72.
56. Kalariti, N.; Lembessis, P.; Koutsilieris, M., Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Research 2004, 24 (6), 3923-9. (Pubitemid 40468687)
57. Chang, H. J.; Yoo, B. C.; Lim, S. B.; Jeong, S. Y.; Kim, W. H.; Park, J. G., Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2005, 11 (9), 3288-95.
58. Park, S. Y.; Lee, S. A.; Han, I. H.; Yoo, B. C.; Lee, S. H.; Park, J. Y.; Cha, I. H.; Kim, J.; Choi, S. W., Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncology Reports 2007, 17 (1), 81-7.
59. Pissimissis, N.; Papageorgiou, E.; Lembessis, P.; Armakolas, A.; Koutsilieris, M., The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 2009, 29 (1), 371-7.
60. Hinoi, E.; Takarada, T.; Ueshima, T.; Tsuchihashi, Y.; Yoneda, Y., Glutamate signaling in peripheral tissues. European Journal of Biochemistry / FEBS 2004, 271 (1), 1-13.
61. Wu, K. K., Regulation of endothelial nitric oxide synthase activity and gene expression. Annals of the New York Academy of Sciences 2002, 962, 122-30. (Pubitemid 34592306)
62. Fleming, I.; Busse, R., Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2003, 284 (1), R1-12.
63. Abdul, M.; Hoosein, N., N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol 2005, 205 (3), 125-8. (Pubitemid 41803689)
64. Legros, H.; Launay, S.; Roussel, B. D.; Marcou-Labarre, A.; Calbo, S.; Catteau, J.; Leroux, P.; Boyer, O.; Ali, C.; Marret, S.; Vivien, D.; Laudenbach, V., Newborn- and adult-derived brain microvascular endothelial cells show age-related differences in phenotype and glutamate-evoked protease release. Journal of Cerebral Blood Flow and Metabolism 2009, 29 (6), 1146-58.
65. Neuhaus, W.; Freidl, M.; Szkokan, P.; Berger, M.; Wirth, M.; Winkler, J.; Gabor, F.; Pifl, C.; Noe, C. R., Effects of NMDA receptor modulators on a blood-brain barrier in vitro model. Brain Research 2011, 1394, 49-61.
66. Filosa, J. A.; Nelson, M. T.; Gonzalez Bosc, L. V., Activity-dependent NFATc3 nuclear accumulation in pericytes from cortical parenchymal microvessels. American Journal of Physiology. Cell Physiology 2007, 293 (6), C1797-805. (Pubitemid 350255074)
67. Collard, C. D.; Park, K. A.; Montalto, M. C.; Alapati, S.; Buras, J. A.; Stahl, G. L.; Colgan, S. P., Neutrophil-derived glutamate regulates vascular endothelial barrier function. The Journal of Biological Chemistry 2002, 277 (17), 14801-11. (Pubitemid 34952552)
68. Krizbai, I. A.; Deli, M. A.; Pestenacz, A.; Siklos, L.; Szabo, C. A.; Andras, I.; Joo, F., Expression of glutamate receptors on cultured cerebral endothelial cells. Journal of Neuroscience Research 1998, 54 (6), 814-9. (Pubitemid 28544382)
69. Ross, J. S.; Sheehan, C. E.; Fisher, H. A.; Kaufman, R. P., Jr.; Kaur, P.; Gray, K.; Webb, I.; Gray, G. S.; Mosher, R.; Kallakury, B. V., Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003, 9 (17), 6357-62. (Pubitemid 38031820)
70. Ashina, M.; Jorgensen, M.; Stallknecht, B.; Mork, H.; Bendtsen, L.; Pedersen, J. F.; Olesen, J.; Jensen, R., No release of interstitial glutamate in experimental human model of muscle pain. European Journal of Pain 2005, 9 (3), 337-43. (Pubitemid 40615713)
71. Nedergaard, M.; Takano, T.; Hansen, A. J., Beyond the role of glutamate as a neurotransmitter. Nature Reviews. Neuroscience 2002, 3 (9), 748-55. (Pubitemid 135706680)
72. Gill, S. S.; Mueller, R. W.; McGuire, P. F.; Pulido, O. M., Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicologic Pathology 2000, 28 (2), 277-84. (Pubitemid 30173835)
73. Dale, L. B.; Babwah, A. V.; Ferguson, S. S., Mechanisms of metabotropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochemistry International 2002, 41 (5), 319-26.
74. Francesconi, A.; Kumari, R.; Zukin, R. S., Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway. The Journal of Neuroscience 2009, 29 (11), 3590-602.
75. Sitcheran, R.; Comb, W. C.; Cogswell, P. C.; Baldwin, A. S., Essential role for epidermal growth factor receptor in glutamate receptor signaling to NF-kappaB. Molecular and Cellular Biology 2008, 28 (16), 5061-70.
76. Sobrio, F.; Gilbert, G.; Perrio, C.; Barre, L.; Debruyne, D., PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development. Mini Reviews in Medicinal Chemistry 2010, 10 (9), 870-86.
77. Wang, J. Q.; Tueckmantel, W.; Zhu, A.; Pellegrino, D.; Brownell, A. L., Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2- pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse 2007, 61 (12), 951-61.
78. Treyer, V.; Streffer, J.; Wyss, M. T.; Bettio, A.; Ametamey, S. M.; Fischer, U.; Schmidt, M.; Gasparini, F.; Hock, C.; Buck, A., Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. Journal of Nuclear Medicine 2007, 48 (7), 1207-15. (Pubitemid 47052662)
79. Wyss, M. T.; Ametamey, S. M.; Treyer, V.; Bettio, A.; Blagoev, M.; Kessler, L. J.; Burger, C.; Weber, B.; Schmidt, M.; Gasparini, F.; Buck, A., Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator. NeuroImage 2007, 35 (3), 1086-92. (Pubitemid 46509846)
80. Ametamey, S. M.; Kessler, L. J.; Honer, M.; Wyss, M. T.; Buck, A.; Hintermann, S.; Auberson, Y. P.; Gasparini, F.; Schubiger, P. A., Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. Journal of Nuclear Medicine 2006, 47 (4), 698-705. (Pubitemid 46768472)
81. Patel, S.; Ndubizu, O.; Hamill, T.; Chaudhary, A.; Burns, H. D.; Hargreaves, R.; Gibson, R. E., Screening Cascade and Development of Potential Positron Emission Tomography Radiotracers for mGluR5: In vitro and In vivo Characterization. Mol Imaging Biol 2005, 1-10.
82. Hamill, T. G.; Krause, S.; Ryan, C.; Bonnefous, C.; Govek, S.; Seiders, T. J.; Cosford, N. D.; Roppe, J.; Kamenecka, T.; Patel, S.; Gibson, R. E.; Sanabria, S.; Riffel, K.; Eng, W.; King, C.; Yang, X.; Green, M. D.; O'Malley, S. S.; Hargreaves, R.; Burns, H. D., Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005, 56 (4), 205-16. (Pubitemid 40656643)
83. Hostetler, E. D.; Eng, W.; Joshi, A. D.; Sanabria-Bohorquez, S.; Kawamoto, H.; Ito, S.; O'Malley, S.; Krause, S.; Ryan, C.; Patel, S.; Williams, M.; Riffel, K.; Suzuki, G.; Ozaki, S.; Ohta, H.; Cook, J.; Burns, H. D.; Hargreaves, R., Synthesis, characterization, and monkey PET studies of [(1)F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse 2011, 65 (2), 125-35.
84. Satoh, A.; Nagatomi, Y.; Hirata, Y.; Ito, S.; Suzuki, G.; Kimura, T.; Maehara, S.; Hikichi, H.; Satow, A.; Hata, M.; Ohta, H.; Kawamoto, H., Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino) pyrimidin-4-yl]-1, 3-thiazol-2-yl]-N-methy lbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorganic & Medicinal Chemistry Letters 2009, 19 (18), 5464-8.
85. Huang, Y.; Narendran, R.; Bischoff, F.; Guo, N.; Zhu, Z.; Bae, S. A.; Lesage, A. S.; Laruelle, M., A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-ethyl-2-[11C]methyl-6- quinolinyl)(cis- 4-methoxycyclohexyl)methanone. Journal of Medicinal Chemistry 2005, 48 (16), 5096-9. (Pubitemid 41113895)
86. Glunde, K.; Pathak, A. P.; Bhujwalla, Z. M., Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med 2007, 13 (7), 287-97. (Pubitemid 47017002)
87. Higgins, L. J.; Pomper, M. G., The evolution of imaging in cancer: current state and future challenges. Semin Oncol 2011, 38 (1), 3-15.
88. Weissleder, R.; Pittet, M. J., Imaging in the era of molecular oncology. Nature 2008, 452 (7187), 580-9. (Pubitemid 351483372)
89. Weber, W. A.; Grosu, A. L.; Czernin, J., Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nat Clin Pract Oncol 2008, 5 (3), 160-70.
90. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J., Cancer statistics, 2007. CA Cancer J Clin 2007, 57 (1), 43-66. (Pubitemid 46148091)
91. Worldwide Prostate Cancer Statistics. http://globocan.iarc.fr/factsheets/ cancers/prostate.asp.
92. Hofer, C.; Laubenbacher, C.; Block, T.; Breul, J.; Hartung, R.; Schwaiger, M., Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999, 36 (1), 31-5. (Pubitemid 29265277)
93. Yeh, S. D.; Imbriaco, M.; Larson, S. M.; Garza, D.; Zhang, J. J.; Kalaigian, H.; Finn, R. D.; Reddy, D.; Horowitz, S. M.; Goldsmith, S. J.; Scher, H. I., Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996, 23 (6), 693-7. (Pubitemid 26342473)
94. Morris, M. J.; Akhurst, T.; Osman, I.; Nunez, R.; Macapinlac, H.; Siedlecki, K.; Verbel, D.; Schwartz, L.; Larson, S. M.; Scher, H. I., Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002, 59 (6), 913-8. (Pubitemid 34522186)
95. Schoder, H.; Herrmann, K.; Gonen, M.; Hricak, H.; Eberhard, S.; Scardino, P.; Scher, H. I.; Larson, S. M., 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005, 11 (13), 4761-9. (Pubitemid 41557196)
96. Morris, M. J.; Akhurst, T.; Larson, S. M.; Ditullio, M.; Chu, E.; Siedlecki, K.; Verbel, D.; Heller, G.; Kelly, W. K.; Slovin, S.; Schwartz, L.; Scher, H. I., Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005, 11 (9), 3210-6. (Pubitemid 40627867)
97. Grant, F. D.; Fahey, F. H.; Packard, A. B.; Davis, R. T.; Alavi, A.; Treves, S. T., Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008, 49 (1), 68-78.
98. Even-Sapir, E.; Mishani, E.; Flusser, G.; Metser, U., 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007, 37 (6), 462-9. (Pubitemid 47505220)
99. Even-Sapir, E.; Metser, U.; Mishani, E.; Lievshitz, G.; Lerman, H.; Leibovitch, I., The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47 (2), 287-97. (Pubitemid 46780894)
100. CMS National Coverage Analysis (NCA) for Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer http://www.cms.gov/medicare- coverage-database/details/nca-details.aspx?NCAId=233&NcaName= Positron+Emission+Tomography+(NaF-18)+to+Identify+Bone+Metastasis+of+Cancer& NCDId=331&ncdver=3&IsPopup=y&.
101. Hara, T.; Bansal, A.; DeGrado, T. R., Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006, 5 (4), 498-509. (Pubitemid 46142823)
102. Ramirez de Molina, A.; Rodriguez-Gonzalez, A.; Gutierrez, R.; Martinez-Pineiro, L.; Sanchez, J.; Bonilla, F.; Rosell, R.; Lacal, J., Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296 (3), 580-3.
103. Roivainen, A.; Forsback, S.; Gronroos, T.; Lehikoinen, P.; Kahkonen, M.; Sutinen, E.; Minn, H., Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000, 27 (1), 25-32. (Pubitemid 30097256)
104. Beer, A. J.; Eiber, M.; Souvatzoglou, M.; Schwaiger, M.; Krause, B. J., Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011, 12 (2), 181-91.
105. Giovacchini, G.; Picchio, M.; Coradeschi, E.; Scattoni, V.; Bettinardi, V.; Cozzarini, C.; Freschi, M.; Fazio, F.; Messa, C., [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008, 35 (6), 1065-73.
106. Sutinen, E.; Nurmi, M.; Roivainen, A.; Varpula, M.; Tolvanen, T.; Lehikoinen, P.; Minn, H., Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004, 31 (3), 317-24. (Pubitemid 38314074)
107. Souvatzoglou, M.; Weirich, G.; Schwarzenboeck, S.; Maurer, T.; Schuster, T.; Bundschuh, R. A.; Eiber, M.; Herrmann, K.; Kuebler, H.; Wester, H. J.; Hoefler, H.; Gschwend, J.; Schwaiger, M.; Treiber, U.; Krause, B. J., The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011, 17 (11), 3751-9.
108. Piert, M.; Park, H.; Khan, A.; Siddiqui, J.; Hussain, H.; Chenevert, T.; Wood, D.; Johnson, T.; Shah, R. B.; Meyer, C., Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009, 50 (10), 1585-93.
109. Scher, B.; Seitz, M.; Albinger, W.; Tiling, R.; Scherr, M.; Becker, H. C.; Souvatzogluou, M.; Gildehaus, F. J.; Wester, H. J.; Dresel, S., Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34 (1), 45-53. (Pubitemid 44885553)
110. Testa, C.; Schiavina, R.; Lodi, R.; Salizzoni, E.; Corti, B.; Farsad, M.; Kurhanewicz, J.; Manferrari, F.; Brunocilla, E.; Tonon, C.; Monetti, N.; Castellucci, P.; Fanti, S.; Coe, M.; Grigioni, W. F.; Martorana, G.; Canini, R.; Barbiroli, B., Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007, 244 (3), 797-806. (Pubitemid 47292091)
111. Kwee, S. A.; Thibault, G. P.; Stack, R. S.; Coel, M. N.; Furusato, B.; Sesterhenn, I. A., Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer. Mol Imaging 2008, 7 (1), 12-20.
112. Kwee, S. A.; Wei, H.; Sesterhenn, I.; Yun, D.; Coel, M. N., Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006, 47 (2), 262-9. (Pubitemid 46780891)
113. Igerc, I.; Kohlfurst, S.; Gallowitsch, H. J.; Matschnig, S.; Kresnik, E.; Gomez-Segovia, I.; Lind, P., The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35 (5), 976-83.
114. de Jong, I. J.; Pruim, J.; Elsinga, P. H.; Vaalburg, W.; Mensink, H. J., 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003, 44 (1), 32-8; discussion 38-9.
115. Scattoni, V.; Picchio, M.; Suardi, N.; Messa, C.; Freschi, M.; Roscigno, M.; Da Pozzo, L.; Bocciardi, A.; Rigatti, P.; Fazio, F., Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52 (2), 423-9. (Pubitemid 46963456)
116. Krause, B. J.; Souvatzoglou, M.; Tuncel, M.; Herrmann, K.; Buck, A. K.; Praus, C.; Schuster, T.; Geinitz, H.; Treiber, U.; Schwaiger, M., The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35 (1), 18-23. (Pubitemid 350234152)
117. Tuncel, M.; Souvatzoglou, M.; Herrmann, K.; Stollfuss, J.; Schuster, T.; Weirich, G.; Wester, H. J.; Schwaiger, M.; Krause, B. J., [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008, 35 (6), 689-95.
118. Cimitan, M.; Bortolus, R.; Morassut, S.; Canzonieri, V.; Garbeglio, A.; Baresic, T.; Borsatti, E.; Drigo, A.; Trovo, M. G., [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33 (12), 1387-98. (Pubitemid 44885404)
119. Bauman, G.; Belhocine, T.; Kovacs, M.; Ward, A.; Beheshti, M.; Rachinsky, I., (18)F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2011.
120. Vavere, A. L.; Kridel, S. J.; Wheeler, F. B.; Lewis, J. S., 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008, 49 (2), 327-34. (Pubitemid 351225673)
121. Nanni, C.; Castellucci, P.; Farsad, M.; Rubello, D.; Fanti, S., 11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imaging 2007, 34 (10), 1704-5.
122. Albrecht, S.; Buchegger, F.; Soloviev, D.; Zaidi, H.; Vees, H.; Khan, H. G.; Keller, A.; Bischof Delaloye, A.; Ratib, O.; Miralbell, R., (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007, 34 (2), 185-96. (Pubitemid 46147501)
123. Sandblom, G.; Sorensen, J.; Lundin, N.; Haggman, M.; Malmstrom, P. U., Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006, 67 (5), 996-1000.
124. Wachter, S.; Tomek, S.; Kurtaran, A.; Wachter-Gerstner, N.; Djavan, B.; Becherer, A.; Mitterhauser, M.; Dobrozemsky, G.; Li, S.; Potter, R.; Dudczak, R.; Kletter, K., 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006, 24 (16), 2513-9. (Pubitemid 46630628)
125. Morris, M. J.; Scher, H. I., (11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34 (2), 181-4. (Pubitemid 46147500)
126. Matthies, A.; Ezziddin, S.; Ulrich, E. M.; Palmedo, H.; Biersack, H. J.; Bender, H.; Guhlke, S., Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004, 31 (5), 797. (Pubitemid 38647921)
127. Schuster, D. M.; Votaw, J. R.; Nieh, P. T.; Yu, W.; Nye, J. A.; Master, V.; Bowman, F. D.; Issa, M. M.; Goodman, M. M., Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007, 48 (1), 56-63. (Pubitemid 47555376)
128. Schuster, D. M.; Savir-Baruch, B.; Nieh, P. T.; Master, V. A.; Halkar, R. K.; Rossi, P. J.; Lewis, M. M.; Nye, J. A.; Yu, W.; Bowman, F. D.; Goodman, M. M., Detection of recurrent prostate carcinoma with anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 2011, 259 (3), 852-61.
129. Okudaira, H.; Shikano, N.; Nishii, R.; Miyagi, T.; Yoshimoto, M.; Kobayashi, M.; Ohe, K.; Nakanishi, T.; Tamai, I.; Namiki, M.; Kawai, K., Putative transport mechanism and intracellular fate of trans-1-amino-3-18F- fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 2011 52 (5), 822-9.
130. Dehdashti, F.; Picus, J.; Michalski, J. M.; Dence, C. S.; Siegel, B. A.; Katzenellenbogen, J. A.; Welch, M. J., Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005, 32 (3), 344-50. (Pubitemid 40562127)
131. Larson, S. M.; Morris, M.; Gunther, I.; Beattie, B.; Humm, J. L.; Akhurst, T. A.; Finn, R. D.; Erdi, Y.; Pentlow, K.; Dyke, J.; Squire, O.; Bornmann, W.; McCarthy, T.; Welch, M.; Scher, H., Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004, 45 (3), 366-73. (Pubitemid 47618608)
132. Beattie, B. J.; Smith-Jones, P. M.; Jhanwar, Y. S.; Schoder, H.; Schmidtlein, C. R.; Morris, M. J.; Zanzonico, P.; Squire, O.; Meirelles, G. S.; Finn, R.; Namavari, M.; Cai, S.; Scher, H. I.; Larson, S. M.; Humm, J. L., Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha- dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med 2010, 51 (2), 183-92.
133. Toth, G.; Lengyel, Z.; Balkay, L.; Salah, M. A.; Tron, L.; Toth, C., Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005, 173 (1), 66-9; discussion 69.
134. Sun, H.; Sloan, A.; Mangner, T. J.; Vaishampayan, U.; Muzik, O.; Collins, J. M.; Douglas, K.; Shields, A. F., Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005, 32 (1), 15-22. (Pubitemid 40142774)
135. Oyama, N.; Ponde, D. E.; Dence, C.; Kim, J.; Tai, Y. C.; Welch, M. J., Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004, 45 (3), 519-25. (Pubitemid 47618630)
136. Wu, A. M.; Olafsen, T., Antibodies for molecular imaging of cancer. Cancer J 2008, 14 (3), 191-7.
137. Goldenberg, D. M.; Sharkey, R. M., Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006, 50 (4), 248-64. (Pubitemid 46157607)
138. Bostwick, D. G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G. P., Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82 (11), 2256-61. (Pubitemid 28240834)
139. Akhtar, N. H.; Pail, O.; Saran, A.; Tyrell, L.; Tagawa, S. T., Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012, 2012, 973820.
140. Ellis, R. J.; Kaminsky, D. A.; Zhou, E. H.; Fu, P.; Chen, W. D.; Brelin, A.; Faulhaber, P. F.; Bodner, D., Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81 (1), 29-34.
141. Zuckier, L. S.; DeNardo, G. L., Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997, 27 (1), 10-29. (Pubitemid 27163474)
142. Mease, R. C., Radionuclide based imaging of prostate cancer. Curr Top Med Chem 2010, 10 (16), 1600-16.
143. Troyer, J. K.; Beckett, M. L.; Wright, G. L., Jr., Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997, 30 (4), 232-42.
144. Bander, N. H.; Nanus, D. M.; Milowsky, M. I.; Kostakoglu, L.; Vallabahajosula, S.; Goldsmith, S. J., Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003, 30 (5), 667-76.
145. Haseman, M. K.; Rosenthal, S. A.; Polascik, T. J., Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm 2000, 15 (2), 131-40. (Pubitemid 30305964)
146. Jain, R. K., Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999, 1, 241-63. (Pubitemid 129740012)
147. Sodee, D. B.; Sodee, A. E.; Bakale, G., Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007, 37 (1), 17-28. (Pubitemid 44854756)
148. Manyak, M. J., Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther 2008, 8 (2), 175-81. (Pubitemid 351385907)
149. Vallabhajosula, S.; Kuji, I.; Hamacher, K. A.; Konishi, S.; Kostakoglu, L.; Kothari, P. A.; Milowski, M. I.; Nanus, D. M.; Bander, N. H.; Goldsmith, S. J., Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005, 46 (4), 634-41. (Pubitemid 41716408)
150. Smith-Jones, P. M.; Vallabahajosula, S.; Goldsmith, S. J.; Navarro, V.; Hunter, C. J.; Bastidas, D.; Bander, N. H., In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000, 60 (18), 5237-43.
151. Bander, N. H.; Trabulsi, E. J.; Kostakoglu, L.; Yao, D.; Vallabhajosula, S.; Smith-Jones, P.; Joyce, M. A.; Milowsky, M.; Nanus, D. M.; Goldsmith, S. J., Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003, 170 (5), 1717-21. (Pubitemid 37254913)
152. Bander, N. H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J., Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005, 23 (21), 4591-601. (Pubitemid 46224061)
153. Nakajima, T.; Mitsunaga, M.; Bander, N. H.; Heston, W. D.; Choyke, P. L.; Kobayashi, H., Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem 2011, 22 (8), 1700-5.
154. Alt, K.; Wiehr, S.; Ehrlichmann, W.; Reischl, G.; Wolf, P.; Pichler, B. J.; Elsasser-Beile, U.; Buhler, P., High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010, 70 (13), 1413-21.
155. Wolf, P.; Freudenberg, N.; Buhler, P.; Alt, K.; Schultze-Seemann, W.; Wetterauer, U.; Elsasser-Beile, U., Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010, 70 (5), 562-9.
156. Elsasser-Beile, U.; Reischl, G.; Wiehr, S.; Buhler, P.; Wolf, P.; Alt, K.; Shively, J.; Judenhofer, M. S.; Machulla, H. J.; Pichler, B. J., PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009, 50 (4), 606-11.
157. Cerchia, L.; Giangrande, P. H.; McNamara, J. O.; de Franciscis, V., Cell-specific aptamers for targeted therapies. Methods Mol Biol 2009, 535, 59-78.
158. Hicke, B. J.; Stephens, A. W.; Gould, T.; Chang, Y. F.; Lynott, C. K.; Heil, J.; Borkowski, S.; Hilger, C. S.; Cook, G.; Warren, S.; Schmidt, P. G., Tumor targeting by an aptamer. J Nucl Med 2006, 47 (4), 668-78. (Pubitemid 46768469)
159. Vorhies, J. S.; Nemunaitis, J. J., Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics 2007, 1 (4), 367-76.
160. Lupold, S. E.; Hicke, B. J.; Lin, Y.; Coffey, D. S., Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002, 62 (14), 4029-33. (Pubitemid 34791070)
161. Bagalkot, V.; Farokhzad, O. C.; Langer, R.; Jon, S., An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 2006, 45 (48), 8149-52. (Pubitemid 44974149)
162. Dassie, J. P.; Liu, X. Y.; Thomas, G. S.; Whitaker, R. M.; Thiel, K. W.; Stockdale, K. R.; Meyerholz, D. K.; McCaffrey, A. P.; McNamara, J. O., 2nd; Giangrande, P. H., Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27 (9), 839-49.
163. Ni, X.; Zhang, Y.; Ribas, J.; Chowdhury, W. H.; Castanares, M.; Zhang, Z.; Laiho, M.; DeWeese, T. L.; Lupold, S. E., Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011, 121 (6), 2383-90.
164. Kim, D.; Jeong, Y. Y.; Jon, S., A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010, 4 (7), 3689-96.
165. Pastor, F.; Kolonias, D.; McNamara Ii, J. O.; Gilboa, E., Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers. Mol Ther 2011.
166. Chu, T. C.; Marks, J. W., 3rd; Lavery, L. A.; Faulkner, S.; Rosenblum, M. G.; Ellington, A. D.; Levy, M., Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006, 66 (12), 5989-92.
167. Lupold, S. E.; Hicke, B. J.; Lin, Y.; Coffey, D. S., Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002, 62 (14), 4029-33. (Pubitemid 34791070)
168. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R., Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103 (16), 6315-20.
169. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R., Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004, 64 (21), 7668-72. (Pubitemid 39446893)
170. Wang, A. Z.; Bagalkot, V.; Vasilliou, C. C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, M.; Yuet, K.; Cima, M. J.; Langer, R.; Kantoff, P. W.; Bander, N. H.; Jon, S.; Farokhzad, O. C., Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3 (9), 1311-5.
171. Zhang, L.; Radovic-Moreno, A. F.; Alexis, F.; Gu, F. X.; Basto, P. A.; Bagalkot, V.; Jon, S.; Langer, R. S.; Farokhzad, O. C., Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007, 2 (9), 1268-71.
172. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J., Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A 2008, 105 (45), 17356-61.
173. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P. W.; Langer, R.; Farokhzad, O. C., Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007, 7 (10), 3065-70. (Pubitemid 350132931)
174. Rockey, W. M.; Huang, L.; Kloepping, K. C.; Baumhover, N. J.; Giangrande, P. H.; Schultz, M. K., Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem 2011.
175. Barinka, C.; Byun, Y.; Dusich, C. L.; Banerjee, S. R.; Chen, Y.; Castanares, M.; Kozikowski, A. P.; Mease, R. C.; Pomper, M. G.; Lubkowski, J., Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem 2008, 51 (24), 7737-43.
176. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J., Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II. Journal of Medicinal Chemistry 2007, 50 (14), 3267-3273. (Pubitemid 47065975)
177. Barinka, C.; Starkova, J.; Konvalinka, J.; Lubkowski, J., A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007, 63 (Pt 3), 150-3. (Pubitemid 46438673)
178. Davis, M. I.; Bennett, M. J.; Thomas, L. M.; Bjorkman, P. J., Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A 2005, 102 (17), 5981-6. (Pubitemid 40594241)
179. Mesters, J. R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R., Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo J 2006, 25 (6), 1375-84.
180. Mesters, J. R.; Henning, K.; Hilgenfeld, R., Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr 2007, 63 (Pt 4), 508-13. (Pubitemid 46465946)
181. Supuran, C., Winum, J-Y, Drug Design of Zinc-Enzyme inhibitors. Chapter 36 Recent Deveopment of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII). . John Wiley & SonsHoboken, New Jersey, Byun, Y., Mease, R.C., Lupold, S.E., Pomper, M.G. 2009.
182. Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P., NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005, 4 (12), 1015-26.
183. Wang, H.; Byun, Y.; Barinka, C.; Pullambhatla, M.; Bhang, H. E.; Fox, J. J.; Lubkowski, J.; Mease, R. C.; Pomper, M. G., Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 2010, 20 (1), 392-7.
184. Slusher, B. S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F., Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999, 5 (12), 1396-402.
185. Jackson, P. F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A., Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 1996, 39 (2), 619-22. (Pubitemid 26041474)
186. Majer, P.; Jackson, P. F.; Delahanty, G.; Grella, B. S.; Ko, Y. S.; Li, W.; Liu, Q.; Maclin, K. M.; Polakova, J.; Shaffer, K. A.; Stoermer, D.; Vitharana, D.; Wang, E. Y.; Zakrzewski, A.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Burak, E.; Limsakun, T.; Tsukamoto, T., Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 2003, 46 (10), 1989-96. (Pubitemid 36532241)
187. Anderson, M. O.; Wu, L. Y.; Santiago, N. M.; Moser, J. M.; Rowley, J. A.; Bolstad, E. S.; Berkman, C. E., Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 2007, 15 (21), 6678-86. (Pubitemid 47385247)
188. Liu, T.; Wu, L. Y.; Kazak, M.; Berkman, C. E., Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 2008, 68 (9), 955-64. (Pubitemid 351794160)
189. Maung, J.; Mallari, J. P.; Girtsman, T. A.; Wu, L. Y.; Rowley, J. A.; Santiago, N. M.; Brunelle, A. N.; Berkman, C. E., Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 2004, 12 (18), 4969-79. (Pubitemid 39164405)
190. Kozikowski, A. P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T., Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 2001, 44 (3), 298-301. (Pubitemid 32113579)
191. Humblet, V.; Lapidus, R.; Williams, L. R.; Tsukamoto, T.; Rojas, C.; Majer, P.; Hin, B.; Ohnishi, S.; De Grand, A. M.; Zaheer, A.; Renze, J. T.; Nakayama, A.; Slusher, B. S.; Frangioni, J. V., High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005, 4 (4), 448-62. (Pubitemid 43143785)
192. Liu, T.; Wu, L. Y.; Hopkins, M. R.; Choi, J. K.; Berkman, C. E., A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 2010, 20 (23), 7124-6.
193. Lapi, S. E.; Wahnishe, H.; Pham, D.; Wu, L. Y.; Nedrow-Byers, J. R.; Liu, T.; Vejdani, K.; VanBrocklin, H. F.; Berkman, C. E.; Jones, E. F., Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 2009, 50 (12), 2042-8.
194. Pomper, M. G.; Musachio, J. L.; Zhang, J.; Scheffel, U.; Zhou, Y.; Hilton, J.; Maini, A.; Dannals, R. F.; Wong, D. F.; Kozikowski, A. P., 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002, 1 (2), 96-101.
195. Foss, C. A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R. T.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G., Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005, 11 (11), 4022-8. (Pubitemid 40791565)
196. Mease, R. C.; Dusich, C. L.; Foss, C. A.; Ravert, H. T.; Dannals, R. F.; Seidel, J.; Prideaux, A.; Fox, J. J.; Sgouros, G.; Kozikowski, A. P.; Pomper, M. G., N-[N-[(S)-1, 3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-Lcysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008, 14 (10), 3036-43.
197. Dusich, C. L., Chen, Y., Pullambhatla, M., Nimmagadda, S., Foss, C.A., Fox, J.J., Castanares, M., Mease, R.C., Pomper, M.G., Synthesis and in-vivo evaluation of 2-{-[1-carboxy-2-(4-[125I]iodo-benzylsulfanyl)-ethyl]-ureido}- pentanedioic acid) [125I]DCFBC). Journal of Labelled Compounds and Radiopharmaceuticals 2009, 52 (Supplement 1), S18 (abstract).
198. Chen, Y.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J. J.; Castanares, M.; Lupold, S. E.; Babich, J. W.; Mease, R. C.; Pomper, M. G., Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008, 51 (24), 7933-43.
199. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W., Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Res 2009.
200. Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Zimmerman, C. N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J. W., A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009, 52 (2), 347-57.
201. 18F]DCFPyL for PSMA-targeted imaging of prostate cancer. J. Nucl. Med. (Abstract) 2011, 52 (Supplement 1), 88P.
202. Barrett, J. A.; LaFrance, N.; Coleman, R. E.; Goldsmith, S. J.; Stubbs, J. B.; Petry, N. A.; Vallabhajosula, S.; Maresca, K. P.; Femia, F. J.; Babich, J. W., Targeting metastatic prostate cancer [PCa] in patients with 123I-MIP1072 and 123I-MIP1095. J Nucl Med 2009, 50S, 136P.
203. Cho SY, Mease R., Holt D, Dannals RF, Eisenberger M, Rodriguez R, Carducci M, Rojas C, Slusher BS, Pomper MG., Initial clinical assessment of DCFBC-PET for metastatic prostate cancer (PCa). (Abstract). J. Nuc. Med. 2011, 52 (Supplement 1), 12P.
204. Banerjee, S. R., Pullambhatla, M., Byun, Y., Green, G., Fox, J.J., Horti, A.G., Mease, R., Pomper, M.G., Ga-68- and In-111-labeled small molecule inhibitors of PSMA for prostate cancer imaging. Journal of Labelled Compounds and Radiopharmaceuticals 2009, 52 (Supplement 1), S19 (abstract).
205. Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G., Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008, 51 (15), 4504-17.
206. 99mTc-Labeled inhibitors for prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Nucl. Med. (Abstract) 2011, 52 (Supplement 1), 88P.
207. Chen, Y.; Dhara, S.; Banerjee, S. R.; Byun, Y.; Pullambhatla, M.; Mease, R. C.; Pomper, M. G., A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009, 390 (3), 624-9.
208. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Foss, C. A.; Green, G.; Fox, J. J.; Lupold, S. E.; Mease, R. C.; Pomper, M. G., Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl 2011, 50, In press.
209. Murelli, R. P.; Zhang, A. X.; Michel, J.; Jorgensen, W. L.; Spiegel, D. A., Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate Cancer. J Am Chem Soc 2009, 131(47), 17090-17092.
210. Kularatne, S. A.; Wang, K.; Santhapuram, H. K.; Low, P. S., Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 2009, 6 (3), 780-9.
211. Kularatne, S. A.; Zhou, Z.; Yang, J.; Post, C. B.; Low, P. S., Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm 2009, 6 (3), 790-800.
212. Malik, N.; Machulla, H. J.; Solbach, C.; Winter, G.; Reske, S. N.; Zlatopolskiy, B., Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep). Appl Radiat Isot 2011, 69 (7), 1014-8.
213. Chandran, S. S.; Banerjee, S. R.; Mease, R. C.; Pomper, M. G.; Denmeade, S. R., Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2008, 7 (6), 974-82.
214. Jayaprakash, S.; Wang, X.; Heston, W. D.; Kozikowski, A. P., Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem 2006, 1 (3), 299-302. (Pubitemid 43700288)
215. Kularatne, S. A.; Venkatesh, C.; Santhapuram, H. K.; Wang, K.; Vaitilingam, B.; Henne, W. A.; Low, P. S., Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J Med Chem 2010, 53 (21), 7767-77.
216. 131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeting therapy of prostate cancer (PCa). J. Nucl. Med. (Abstract) 2011, 52 (Supplement), 107P.
217. Slovin, S. F., Emerging role of immunotherapy in the management of prostate cancer. Oncology (Williston Park) 2007, 21 (3), 326-33; discussion 334, 338, 346-8.
218. Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W.; Nie, S., In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22 (8), 969-76. (Pubitemid 39014473)
219. Denmeade, S. R.; Jakobsen, C. M.; Janssen, S.; Khan, S. R.; Garrett, E. S.; Lilja, H.; Christensen, S. B.; Isaacs, J. T., Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003, 95 (13), 990-1000. (Pubitemid 36896716)